Language

Pulmonology

Pulmonary Studies

MultiCare Pulmonary Specialists is a multi-physician group located in Tacoma, WA. The site employs an experienced research team comprised of board certified Pulmonologists, Study Coordinators, and an Administrative Assistant. The site is conveniently located near three hospitals and all clinical research is done on site. In addition, the site has a comprehensive patient database that is connected to all MultiCare facilities.

Research Director:

James R. Taylor, M.D., Medical Director for the site, has over twenty (20) years of research experience and has conducted over 150 trials. Dr. Taylor trained at Stanford University, University of California San Francisco and the University of Washington. Dr. Taylor is board certified in Pulmonary, Critical Care and Internal Medicine, and is the Medical Director of the ICU at Tacoma General Hospital.

Principal Investigators:

James R. Taylor, M.D., Board Certified Internal Medicine, Pulmonary, Critical Care
Stephen C. Ryan, M.D., Board Certified Internal Medicine, Pulmonary, Critical Care, Sleep Medicine

Sub-Investigators:

Arthur R. Knodel, M.D., Board Certified Internal Medicine, Pulmonary, Critical Care, Sleep Medicine
Edward J. LeDoux, M.D., Board Certified Internal Medicine, Pulmonary, Critical Care, Sleep Medicine
Thomas N. Mann, M.D., Board Certified Internal Medicine, Pulmonary, Critical Care
John H. Rowlands, M.D., Board Certified Internal Medicine, Pulmonary, Critical Care, Sleep Medicine

Research Interests:
  • Asthma
  • Allergy & Allergic Rhinitis
  • COPD
  • Smoking Cessation
  • Sleep Disorders
  • Cystic Fibrosis
  • Bronchiectasis

Pulmonary Studies Accepting Participants

Adult - COPD Ethos
Study Number: PT010005-01—A randomized, double-blind, multi-center, parallel group study to assess the efficacy and safety of PT010 relative to PT003 and PT009 on COPD exacerbations over a 52-week treatment period in subjects with moderate to very severe COPD.

Study Info

Principal Investigator(s): Stephen Ryan, MD

Study Coordinator: Juanita Baker, [email protected], 253-403-0366 
Adult - Boehringer Ingelheim COPD
Study Number: Boehringer Ingelheim 1237.35 - A randomized, double-blind, active-controlled parallel group study to evaluate the impact of once daily treatment with orally inhaled tiotropium + olodaterol (5ug/5ug) fixed dose combination compared with tiotropium (5ug) on long term outcomes in patients with chronic obstructive pulmonary disease (COPD) and moderate (GOLD stage ll) lung function impairment.

Principal Investigator(s): Stephen Ryan, MD

Study Coordinator: Jami Smith, [email protected], 253-403-0389
Adult - Energito
Study Number: 1237.63—A randomized, double-blind, double-dummy, active-controlled, multi-center, parallel group study to show the superiority in lung function of 12 weeks once daily treatment with orally inhaled tiotropium+olodaterol fixed dose combination delivered by the Respimat inhaler vs. 12 weeks twice daily treatment with orally inhaled fluticasone propionate+salmeterol fixed dose combination delivered by the Diskus in patients with chronic obstructive pulmonary disease (COPD).

Principal Investigator(s): Stephen Ryan, MD

Study Coordinator: Jami Smith, [email protected], 253-403-0389
Adult - ANDHI
Study NumberD3250C00045—A multi-center, randomized, double-blind, parallel group, placebo-controlled, Phase 3b study to evaluate the safety and efficacy of the Benralizumab 30 mg sc in patients with severe asthma uncontrolled on standard of care treatment.

Study Info

Principal Investigator(s): Stephen Ryan, MD

Study Coordinator: Jami Smith, [email protected], 253-403-0389
Adult - Chiesi CCD-0599AA3-02
Study NumberCCD-0599AA3-02—A 6-week, multi-center, randomized, double-blind, placebo-and active-controlled, parallel group, dose-ranging study to evaluate the efficacy and safety of 4 doses of CHF 5259 pMDI (HFA Glycopyrronium Bromide via Pressurized Metered Dose Inhaler) in subjects with chronic obstructive pulmonary disease (COPD).  

Principal Investigator(s): Stephen Ryan, MD

Study Coordinator: Jami Smith, [email protected], 253-403-0389
Adult - Visterra

Study NumberVIS410-203—A Phase 2b, multi-center, randomized, double-blind, controlled study to evaluate the efficacy and safety of intravenous VIS410 in addition to Oseltamivir (Tamiflu) compared with Oseltamivir alone in hospitalized adults with infulenza A infection requiring oxygen support. 

Principal Investigator(s): Stephen Ryan, MD

Study Coordinator: Jami Smith, [email protected], 253-403-0389

Pediatrics - CTX Prevalence Study

Study Number018CTXX15001—An observational, multi-center study of the prevalence of Cerebrotendinous Xanthomatosis (CTX) in patient populations diagnosed with early onset Idiopathic Bilateral Cataracts.

Study Info

Principal Investigator(s): Michael Raff, MD

Study Coordinator: Dalia Sherif, [email protected], 253-403-2698

Pediatrics - Non-Interventional CF Study

Study NumberCTBM100C2407—A prospective observational study in cystic fibrosis patients with chronic respiratory pseudomonas aeruginosa infection treated with TOBI Podhaler (tobramycin inhalation powder) or other FDA approved inhaler antipseudomonal antibacterial drugs.

Study Info

Principal Investigator(s): David Ricker, MD

Study Coordinator: Juanita Baker, [email protected], 253-403-0366